Agile Therapeutics Announces Pricing of $7.5 Million Public Offering
May 22, 2023 20:00 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., May 22, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) ("Agile Therapeutics" or the "Company"), a women's healthcare company, today announced the pricing of its...
Agile Therapeutics Reports First Quarter 2023 Financial Results And Provides Corporate Update
May 11, 2023 16:05 ET
|
Agile Therapeutics, Inc.
Twirla Delivers Single-Quarter Records for Retail and Non-Retail Demand; Both Channels Up 20% in First Quarter 2023 vs Fourth Quarter 2022 Total OPEX down 8% in First Quarter 2023 vs Fourth...
Agile Therapeutics to Report First Quarter 2023 Financial Results and Provide Business Update on Thursday, May 11, 2023
May 08, 2023 08:00 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., May 08, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced it will report first quarter 2023 financial results after the...
Agile Therapeutics Announces Preliminary Expectations for First Quarter 2023
April 28, 2023 08:01 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., April 28, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced preliminary expectations for first quarter 2023 Twirla®...
Agile Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement
April 26, 2023 09:01 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., April 26, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that it has received a notification letter from the Listing...
Agile Therapeutics Announces 1-For-50 Reverse Stock Split
April 10, 2023 16:30 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., April 10, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) (“Agile”), a women's healthcare company, today announced that its board of directors approved a 1-for-50...
Agile Therapeutics Reports Fourth Quarter & Full Year 2022 Financial Results and Provides Corporate Update
March 22, 2023 16:05 ET
|
Agile Therapeutics, Inc.
Fourth Quarter 2022 Net Revenue Increased 33% from Third Quarter 2022 While GAAP Quarter-Over-Quarter OPEX Decreased 55% and Non-GAAP OPEX Remained Unchanged Twirla Demand and Factory Sales...
Agile Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on Wednesday, March 22, 2023
March 21, 2023 09:05 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., March 21, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced it will report fourth quarter and full year 2022 financial...
Agile Therapeutics Granted 180-Day Extension by Nasdaq to Meet the Minimum Bid Price Requirement
February 27, 2023 08:31 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) (“Agile” or the “Company”), a women's healthcare company, today announced that it has received written...
Agile Therapeutics Provides Clinical Update on Twirla and Status of Pipeline Evaluation
February 01, 2023 08:01 ET
|
Agile Therapeutics, Inc.
FDA Agrees to Extended Milestones for Long-Term Twirla® Safety Study New Publication Supports Eventual Pursuit of AG200-15 Extended Regimen Development Program PRINCETON, N.J., Feb. 01, 2023 ...